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Probiotics — findings challenged
To the Editor: Startling and irresponsible conclusions are
drawn in relation to various probiotic products on the South
African market by the authors of an article in the February
2004 SAMJ entitled ‘An evaluation of nine probiotics available
in South Africa, August 2003’.1
The article fails to do justice to the recognised benefits of
probiotic products and, arising from its inaccuracies and its
apparent subjectivity, issue must be taken with its contents. The
authors level various criticisms against the manufacturers/
distributors of certain probiotic products, including Pharma
Dynamics in relation to its product, Culturelle.
Set out below are pertinent facts omitted by the authors of
the article (one of whom is medical advisor to, and apparently
a shareholder of, Thebe Pharmaceuticals, the sponsor of the
study reported in the article and the South African distributor
of the probiotic product, BioPro Reuteri — a product
favourably evaluated in the article).
1. The study, its methodology and its results are severely
flawed. The sampled products, which are particularly sensitive
to atmospheric conditions and extremes in temperature, were
transported from South Africa to Belgium for analysis under
uncontrolled conditions (‘packed on ice’ in the hold of an
aeroplane, subject to low levels of oxygen and without any
form of monitoring or recording of conditions).
2. The study reported in the article is based on the DGGE
(denaturing gradient gel electrophoresis) testing method. The
method is fundamentally flawed in that is is unable to quantify
the amount of bacteria identified. Thus the quantity of bacteria
referred to in the article (based on the method) cannot be
verified by the testing method.
3. DGGE is not a recognised international standard for the
identification of commercially available probiotic bacteria, and
is therefore unreliable in the final identification of the lactic
acid bacteria strains, and, on the study researcher’s own
version, not to be considered optimal in obtaining a 100%
reliable result.
4. In respect of its product, Culturelle, the manufacturer uses
internationally renowned and approved Bergey’s Manual to
identify lactic acid bacteria strains present in the product. This
method remains recognised and internationally approved for
the identification of commercially available lactic acid bacteria.
5. The certificate of analysis and the underlying data in
respect of the batch of Culturelle to which the article refers
have been verified and comply with European Pharmacopoeia
specifications. Pharma Dynamics conducts repeated periodic
stability testing and verification during product storage to
ensure the continued stability of Culturelle.
6. Culturelle is enteric coated to ensure that the bifido-
bacteria, which are sensitive to acid, are protected during the
passage through the stomach, the product reaching the
intestine before the coating dissolves to release the lactic acid
bacteria. The article fails to detail whether an appropriate
method, taking into consideration the nature of products
tested, was used to release the tested bacteria from the micro-
encapsulated particles.
7. The clear association between at least one of the co-authors
and Thebe Pharmaceuticals casts serious doubts on the
impartiality of the article, the study and its various
conclusions.
The above brief comments and observations raised all
illustrate the numerous and serious concerns that must be
raised in relation to the article and the study to which it refers.
For the sake of the reputation of the SAMJ, it is essential for the
integrity of the journal that a comprehensive peer review
process excludes the publishing of what one is ineluctably led
to conclude is an ‘advertorial’ based on the disparagement of
competitor products.
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Doctors and the medical aid
industry
To the Editor: I would like to add my (slightly humbler) voice
to those of my esteemed colleagues Robert Caldwell1 and N C
Lee.2
Doctors are service providers who have/should have
absolutely no contractual or other obligations to insurance
companies (which, after all, is what medical aids are).
Furthermore, doctors should not be required to be
businessmen, but we are rapidly being forced in that direction.
In this regard surely it must be unethical not to recommend
fees to be charged? That great institution, the HPCSA, is
strangely silent on this issue. How has it come to be that the
medical aid industry has the power to prescribe to us? Above
all, what is SAMA as our only representative organ doing
about it? Public perception is definitely that we are the baddies
(rich, greedy doctors, always wanting more money), and they
remain sublimely ignorant as to the real state of affairs.
Medical aids have frequently shown that this is not a
‘gentleman’s fight’ and they should be handled accordingly. I
have been a SAMA member since my internship and am now a
SASA member as well, but more and more colleagues inform
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